Finally It's Out! What the NICE Position on the AI Use in Evidence Generation and Synthesis Means for HTA Submissions – the Do’s and Don’ts

Speaker(s)

Grammati Sarri, PhD, MSc, DiDS, Cytel, London, UK, Sophia van Beekhuizen, MSc, MPhil, Cytel, Rotterdam, Netherlands and Grace Hsu, MSc, Cytel, Waltham, MA, USA

Presentation Documents

The much-anticipated NICE position statement on the potential AI use in evidence generation and reporting of evidence to be submitted to the agency is finally published. This statement, from a world-class HTA body, opens the door for the wider and more systematic integration of AI tools in evidence development and generation for health technologies submissions. While the agency recognized the potential of these tools in different phases of the evidence preparation (systematic review and evidence synthesis, comparative effectiveness, and real-world analytics), there are many unanswered questions and challenges for manufactures to navigate such as the acceptability bar of integrating such tools in their submissions and assess the level of investment by formally integrating such tools in their preparatory activities.

The moderator will introduce the main points in the NICE AI statement and present some background HEOR research that may have mobilized the agency to publish such statement. The other panelists will present specific opportunities and challenges in translating the NICE position on AI during conducting systematic literature reviews, comparative clinical and cost-effectiveness analysis and using RWE in data analytics. Finally, the moderator will close by presenting a roadmap (checklist) to be used when AI tools are considered in NICE submissions and will open the floor for discussion with the audience.

Sponsor: Cytel

Code

309

Topic

Medical Technologies